Literature DB >> 12112387

Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.

Ling Wang1, David A Eastmond.   

Abstract

Merbarone is a catalytic inhibitor of topoisomerase II (topo II) that has been proposed to act primarily by blocking topo II-mediated DNA cleavage without stabilizing DNA-topo II-cleavable complexes. In this study merbarone was used as a model compound to investigate the genotoxic effects of catalytic inhibitors of topo II. The clastogenic properties of merbarone were evaluated using in vitro and in vivo micronucleus (MN) assays combined with CREST staining. For the in vitro MN assay, ICRF-187, a different type of catalytic inhibitor, and etoposide, a topo II poison, were used for comparison. Treatment of TK6 cells with all three of these drugs resulted in highly significant dose-related increases in kinetochore-lacking MN and, to a lesser extent, kinetochore-containing MN. In addition, a good correlation between p53 accumulation and MN formation was seen in the drug-treated cells. A mouse MN assay was performed to confirm that similar DNA-damaging effects would occur in vivo. Bone marrow smears from merbarone-treated B6C3F1 mice showed a dose-related increase in micronucleated polychromatic erythrocytes with a mean of 26 MN per 1000 cells being seen at the 60 mg/kg dose. Almost all MN lacked a kinetochore signal, indicating that merbarone was predominantly clastogenic under these conditions in vivo. The present study clearly shows that merbarone is genotoxic both in vitro and in vivo, and demonstrates the inaccuracy of earlier statements that merbarone and other catalytic inhibitors block the enzymatic activity of topo II without damaging DNA. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112387     DOI: 10.1002/em.10072

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  13 in total

1.  Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.

Authors:  P Gollapudi; V S Bhat; D A Eastmond
Journal:  Mutat Res       Date:  2019-05-15       Impact factor: 2.433

2.  Single-molecule Förster resonance energy transfer (FRET) analysis discloses the dynamics of the DNA-topoisomerase II (Top2) interaction in the presence of TOP2-targeting agents.

Authors:  Wan-Chen Huang; Chun-Ying Lee; Tao-Shih Hsieh
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

Review 3.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 4.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

Review 5.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

6.  Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line.

Authors:  Adam J Carpenter; Andrew C G Porter
Journal:  Mol Biol Cell       Date:  2004-09-29       Impact factor: 4.138

7.  CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1.

Authors:  Verena Quennet; Andrea Beucher; Olivia Barton; Shunichi Takeda; Markus Löbrich
Journal:  Nucleic Acids Res       Date:  2010-11-17       Impact factor: 16.971

8.  Studying vertebrate topoisomerase 2 function using a conditional knockdown system in DT40 cells.

Authors:  Mark Johnson; Hui Hui Phua; Sophia C Bennett; Jennifer M Spence; Christine J Farr
Journal:  Nucleic Acids Res       Date:  2009-06-03       Impact factor: 16.971

9.  YM155 inhibits topoisomerase function.

Authors:  Mei Hong; Ming-Qiang Ren; Jeane Silva; Ananya Paul; W David Wilson; Carsten Schroeder; Paul Weinberger; John Janik; Zhonglin Hao
Journal:  Anticancer Drugs       Date:  2017-02       Impact factor: 2.389

10.  Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway.

Authors:  Alexei Mikhailov; Mio Shinohara; Conly L Rieder
Journal:  J Cell Biol       Date:  2004-08-09       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.